NCT04365127 is a Phase 1 clinical trial of Progesterone 100 MG in COVID-19, sponsored by Sara Ghandehari.

Who is sponsoring NCT04365127?

NCT04365127 is sponsored by Sara Ghandehari.

What drugs are being tested in NCT04365127?

Interventions in NCT04365127: Progesterone 100 MG.

What condition does NCT04365127 study?

NCT04365127 studies COVID-19, Sars-CoV2.

Is NCT04365127 still recruiting?

NCT04365127 is currently completed. Last updated 27 January 2021.

Last reviewed 2021-01-27 · How we verify

NCT04365127

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Progesterone for the Treatment of COVID-19 in Hospitalized Men

Completed Phase 1 Last updated 27 January 2021

What this trial tests

Phase 1 trial testing Progesterone 100 MG in COVID-19 in 40 participants. Completed in 20 August 2020.

Timeline

27 April 2020

Primary endpoint
20 August 2020

20 August 2020

Quick facts

Lead sponsor	Sara Ghandehari
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	27 April 2020
Primary completion	20 August 2020
Estimated completion	20 August 2020
Sites	1 location across United States

Drugs / interventions tested

Progesterone 100 MG — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →
Sars-CoV2 — all drugs for Sars-CoV2 →

Sponsor

Sara Ghandehari — full company profile →

Who can join

18 and older, male only, with COVID-19 or Sars-CoV2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess safety and efficacy of progesterone for treatment of COVID-19 in hospitalized men.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, et al · · 2020 · cited 246× · PMID 32687918 · DOI 10.1016/j.lfs.2020.118102
Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes.
Mauvais-Jarvis F, Klein SL, Levin ER. · · 2020 · cited 177× · PMID 32730568 · DOI 10.1210/endocr/bqaa127
Androgen sensitivity gateway to COVID-19 disease severity.
Wambier CG, Goren A, Vaño-Galván S, Ramos PM, et al · · 2020 · cited 107× · PMID 32412125 · DOI 10.1002/ddr.21688
ACE2: the molecular doorway to SARS-CoV-2.
Medina-Enríquez MM, Lopez-León S, Carlos-Escalante JA, Aponte-Torres Z, et al · · 2020 · cited 81× · PMID 33380340 · DOI 10.1186/s13578-020-00519-8
A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening.
Gorgulla C, Padmanabha Das KM, Leigh KE, Cespugli M, et al · · 2021 · cited 72× · PMID 33426509 · DOI 10.1016/j.isci.2020.102021
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895
Sex-related differences in COVID-19 lethality.
Penna C, Mercurio V, Tocchetti CG, Pagliaro P. · · 2020 · cited 66× · PMID 32698249 · DOI 10.1111/bph.15207
Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives.
Sarkar C, Mondal M, Torequl Islam M, Martorell M, et al · · 2020 · cited 64× · PMID 33041814 · DOI 10.3389/fphar.2020.572870

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04365127 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sara Ghandehari
Last refreshed: 27 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04365127.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing